Iopamiro 200 (Iopamidol)

Iopamidol contains iodine atoms that strongly absorb X‑rays. When injected intravenously, it distributes in the extracellular fluid and temporarily raises the radiodensity of blood vessels and tissues. This physical attenuation of X‑rays creates a contrast between structures, enabling detailed visualization on CT scans, angiograms, and other imaging modalities.

The dose of Iopamiro 200 is determined by the prescribing physician based on the specific imaging protocol, patient size, and clinical indication. Dosing is individualized and should follow the recommendations of the imaging department and relevant guidelines; no fixed regimen is provided here.

Safety data for Iopamiro 200 in pregnancy and lactation are limited. It should be used only when the potential diagnostic benefit justifies any possible risk to the fetus or infant. Clinicians should discuss the risk‑benefit profile with the patient and consider alternative imaging methods when appropriate.

To order Iopamiro 200, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including any cold‑chain requirements), and import documentation.

Iopamiro 200 contains iopamidol, a non‑ionic, low‑osmolality iodinated contrast agent. Compared with older ionic, high‑osmolality agents, it generally produces fewer immediate adverse reactions and is better tolerated, especially in patients with compromised renal function. Its imaging performance is comparable, providing high‑quality contrast enhancement for a wide range of diagnostic studies.

Iopamiro 200 should be stored at ambient temperature, preferably below 25 °C. Keep the vials in their original packaging, protect them from light and moisture, and avoid freezing. Inspect the solution for particulate matter or discoloration before use, and discard any product that appears compromised.

Iopamiro 200 is administered by intravenous injection, typically using a power injector to deliver a controlled volume at a specific rate as defined by the imaging protocol. The solution may be diluted with compatible sterile fluids according to the procedure requirements, and administration should be performed by trained healthcare professionals.

The most serious risks associated with Iopamiro 200 include severe allergic reactions such as anaphylaxis, contrast‑induced nephropathy leading to acute kidney injury, and rare cardiovascular events like hypotension or arrhythmia. Prompt recognition and management of these reactions are essential, and patients with known risk factors should be closely monitored.

Iopamiro 200 should be avoided in patients with a documented hypersensitivity to iodinated contrast media, severe renal impairment (e.g., eGFR < 30 mL/min/1.73 m²), uncontrolled thyroid disease, or in those who have experienced prior severe reactions to similar agents. Clinicians must assess individual risk factors before administration.